Breaking Finance News

Vetr Inc. announced Pfizer Inc. (NYSE:PFE), bumping up its stock price target to $37.42 today

In a report released on 10/17/2016 Vetr Inc. increased the stock price target of Pfizer Inc. (NYSE:PFE) to $37.42 stating a potential upside of 0.15%.

On 10/13/2016, Vetr Inc. released a statement on Pfizer Inc. (NYSE:PFE) upped the target price from $0.00 to $36.36 that suggested an upside of 0.10%.

Having a price of $32.66, Pfizer Inc. (NYSE:PFE) traded -0.49% lower on the day. With the last close down -5.39% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Pfizer Inc. has recorded a 50-day average of $33.95 and a two hundred day average of $34.35. Volume of trade was down over the average, with 16,923,468 shares of PFE changing hands under the typical 18,715,400

Performance Chart

Pfizer Inc. (NYSE:PFE)

With a total market value of $0, Pfizer Inc. has 52 week low of $28.25 and a 52 week high of $37.39 with a P/E ratio of 28.81 .

In addition to Vetr Inc. reporting its target price, a total of 20 firms have reported on the stock. The consensus target price is $38.58 with 4 firms rating the stock a strong buy, 10 firms rating the stock a buy, 7 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.